Cancer Vaccine Works'Startlingly Well' in Mouse Model Cancer Vaccine Works'Startlingly Well' in Mouse Model

An experimental cancer vaccine that was injected directly into the tumor cured 87 of 90 mice, including some with spontaneous tumors.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

CONCLUSION: These observations emphasize the potential of Flt3L as an adjuvant for colon cancer DNA vaccines. PMID: 30111221 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
AbstractImmunotherapy is rapidly transforming cancer care across a range of tumor types. Although Sipuleucel-T represented the first successful vaccine for the treatment of established cancer, other immunotherapeutic approaches for prostate cancer such as checkpoint inhibitors have been relatively disappointing to date. However, significant promise is on the horizon as there is a wide array trials evaluating immunotherapy in prostate cancer patients. These include both immune checkpoint inhibitors and antigen-specific approaches including vaccines, antibody-drug conjugates, and antitumor antibodies. Furthermore, a better u...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
ConclusionWe demonstrate using a GMP-compliant culture protocol the feasibility of generating high yields of mature DCs in a short time, with a superior immunogenic profile compared with 8-day TNF-α/PGE2–matured DCs, and capable of inducing vigorous cytotoxic T-cell responses to antigen from electroporated mRNA. This method is now being applied in our clinical trial program.
Source: Cytotherapy - Category: Cytology Source Type: research
AbstractHuman papillomavirus (HPV) vaccination has the potential to reduce the burden of anogenital cancers. Vaccine uptake remains suboptimal, especially among young adults. Social determinants of health (SDOH) are societal level conditions that may indirectly influence health behaviors, including HPV vaccination. The purpose of this study was to assess HPV vaccination and SDOH among young adult women and men. The 2016 National Health Interview Survey was restricted to participants ages 18 –26 (n = 3593). The Healthy People 2020 SDOH Framework was used to identify variables for economic stability, heal...
Source: Journal of Community Health - Category: International Medicine & Public Health Source Type: research
Journal of Obstetrics and Gynaecology Research, EarlyView.
Source: Journal of Obstetrics and Gynaecology Research - Category: OBGYN Authors: Source Type: research
Despite the high prevalences of Human Papilloma Virus (HPV) infections and cervical cancer in Nigeria, utilization of the HPV vaccine as a highly effective preventive measure remains low. The aim of this study...
Source: Infectious Agents and Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
ConclusionsWe observed pronounced HPV vaccination initiation disparities among foreign-born women in relation to race/ethnicity and between foreign-born women from minoritized racial/ethnic backgrounds and U.S.-born white women. Research on nativity disparities in HPV vaccination should take into account race/ethnicity, and vice versa. Interventions that seek to facilitate HPV vaccination among foreign-born women are needed and should address the unique needs of those from minoritized racial/ethnic backgrounds to promote cancer equity.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Conditions:   Cutaneous Melanoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Urothelial Carcinoma;   Renal Cell Carcinoma Interventions:   Biological: GEN-009 Adjuvanted Vaccine;   Drug: Nivolumab Sponsor:   Genocea Biosciences, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   HER2+ Breast Cancer Interventions:   Biological: VRP-HER2;   Biological: Pembrolizumab Sponsors:   Herbert Lyerly;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cutaneous Melanoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Urothelial Carcinoma;   Renal Cell Carcinoma Interventions:   Biological: GEN-009 Adjuvanted Vaccine;   Drug: Nivolumab Sponsor:   Genocea Biosciences, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Health | Hematology | Vaccines